A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

NCT03605836 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

590

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder
Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Centanafadine SR
OTHER: Placebo
DRUG: Centanafadine SR

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.